TapewireFind a company

person · Reporting owner

Sinha Vikas

Disclosed activity across 4 companies

Tapewire entity
51945
SEC CIK
0001337845

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BCLS Acquisition Corp.BLSA · Entity 145747DirectorOctober 22, 2020October 22, 2020
Kalaris Therapeutics, Inc.ALVR · Entity 6805Director · See Remarks · 10% ownerFebruary 21, 2025February 24, 2025
Scholar Rock Holding CorpSRRK · Entity 3721Chief Financial OfficerApril 16, 2026April 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BCLS Acquisition Corp.

Report date October 22, 2020 · Filed October 22, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B ordinary sharesSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2020-10-22 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249284) under the heading "Description of Securities--Founder Shares", the shares of Class B ordinary shares, par value $0.0001 per share, will automatically convert into shares of Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Kalaris Therapeutics, Inc.

Report date February 21, 2025 · Filed February 24, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect49,129 Reported balance After 2025-02-21 transaction · row 1
1 source row

Row 1 · 2025-02-21 · Sale · Disposed 303 · Balance 49,129

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Common StockSEC Table I · non-derivativeIndirectSee footnote724,989 Reported balance Holding disclosure · report date 2025-02-21 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 724,989

F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Scholar Rock Holding Corp

Report date April 16, 2026 · Filed April 20, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect619,856 Reported balance After 2026-04-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-04-16 · Sale · Disposed 10,410 · Balance 619,856

F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.

F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.

F2: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Verona Pharma plc

Report date October 07, 2025 · Filed October 08, 2025

Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect0 Last balance in matching sequence After 2025-10-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2025-10-07 · Disposition to issuer · Disposed 94,112 · Balance 0

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

Row 2 · 2025-10-07 · Exercise / conversion · Acquired 72,000 · Balance 72,000

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Row 3 · 2025-10-07 · Disposition to issuer · Disposed 72,000 · Balance 0

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Restricted Share UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-10-07 · Exercise / conversion · Disposed 72,000 · Balance 0

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-04-27Direct0 Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-10-07 · Disposition to issuer · Disposed 384 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2033-04-27Direct0 Reported balance After 2025-10-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-10-07 · Disposition to issuer · Disposed 96,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2034-04-28Direct0 Reported balance After 2025-10-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-10-07 · Disposition to issuer · Disposed 240,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08Direct0 Reported balance After 2025-10-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-10-07 · Disposition to issuer · Disposed 64,000 · Balance 0

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 16, 2026 Filed Apr 20, 2026 22:09 UTC Scholar Rock Holding Corp SRRK · Entity 3721 SaleCommon Stock 10,410 $49.57 $516,070.55
Disclosure

SEC source: 0001104659-26-045582 · tm2612274-2_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 619,856

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSUs") on April 15, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on April 27, 2025. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date.

F2 · balance_after: Consists of 47,835 shares of common stock, 122,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:12 UTC Scholar Rock Holding Corp SRRK · Entity 3721 GrantCommon Stock 47,021 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-013586 · tm266077-7_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,266

F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2027 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

F2 · balance_after: Consists of 33,245 shares of common stock, 147,021 RSUs subject to time-based vesting conditions and 450,000 RSUs subject to performance- and time-based vesting conditions.

Read SEC document
January 13, 2026 Filed Jan 16, 2026 00:58 UTC Scholar Rock Holding Corp SRRK · Entity 3721 SaleCommon Stock 16,755 $42.70 $715,438.50
Disclosure

SEC source: 0001104659-26-004224 · tm263352-4_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 583,245

F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the vesting of restricted stock units subject to performance-and time-based vesting conditions ("PSUs"). The sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Each PSU represents the contingent right to receive upon vesting of the PSU, one share of the Issuer's common stock.

F2 · shares: (continued) The shares vested pursuant to awards that were granted on April 27, 2025. 50,000 shares subject to this PSU vested on January 12, 2026, with an additional 50,000 shares scheduled to vest on April 27, 2027 and the remaining shares vesting in tranches of a combination of performance-based vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four year, provided the Reporting Person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration.

F3 · balance_after: 33,245 shares of common stock, 100,000 restricted stock units and 450,000 PSUs.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 64,000 Not disclosed Strike: $0.78 Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 8

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 64,000 shares

Expires 2031-08-08

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 240,000 Not disclosed Strike: $1.93 Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 7

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 240,000 shares

Expires 2034-04-28

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 96,000 Not disclosed Strike: $2.67 Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 6

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 96,000 shares

Expires 2033-04-27

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerShare Options (Right to Buy) · Derivative 384 Not disclosed Strike: $0.50 Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 5

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 384 shares

Expires 2032-04-27

F6 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F6 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionRestricted Share Unit · Derivative 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · derivative · entry 4

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 72,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F4 · derivative.exercise_price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerOrdinary Shares 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 3

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 72,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · price: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

Read SEC document
October 07, 2025 Filed Oct 8, 2025 20:36 UTC Verona Pharma plc VRNA · Entity 74409 Disposition to issuerOrdinary Shares 94,112 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-097954 · tm2528014-7_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · price: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3 · price: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:17 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionRestricted Stock Units · Derivative 24,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · derivative · entry 3

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Ordinary Shares · 24,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F5 · derivative.exercise_price: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.

F5 · derivative.expiration_date: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:17 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 4,328 $13.14 $56,885.93
Disclosure

SEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,112

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs").

F3 · price: The price reported represents the sale price of the ADSs divided by eight (8).

F4 · balance_after: Consists of 94,112 Ordinary Shares represented by 11,764 ADSs.

Read SEC document
August 01, 2025 Filed Aug 6, 2025 00:17 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 24,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-074382 · tm2522566-2_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:06 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionShare Options (Right to Buy) · Derivative 160,000 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · derivative · entry 3

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 384

Underlying: Ordinary Shares · 160,000 shares

Expires 2032-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F6 · derivative.exercise_date: The option is fully vested.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:06 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 160,000 $9.39 $1,502,928.00
Disclosure

SEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,440

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2024.

F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $9.375 to $9.4263, inclusive (or $75.00 to $75.41 per ADS, inclusive). The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.

F4 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:06 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 160,000 $0.50 $80,608.00
Disclosure

SEC source: 0001104659-25-051986 · tm2515898-2_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 234,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
May 02, 2025 Filed May 6, 2025 21:01 UTC Scholar Rock Holding Corp SRRK · Entity 3721 GrantStock Option (Right to Buy) · Derivative 110,067 $0.00 Strike: $32.91 $0.00
Disclosure

SEC source: 0001104659-25-045114 · tm2513936-2_4seq1.xml · derivative · entry 1

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,067

Underlying: Common Stock · 110,067 shares

Expires 2035-05-02

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on April 27, 2026, with the remainder vesting in twelve equal quarterly installments thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionShare Options (Right to Buy) · Derivative 4,952 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · derivative · entry 6

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,048

Underlying: Ordinary Shares · 4,952 shares

Expires 2032-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F5 · derivative.exercise_date: The option is fully vested.

F4 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionShare Options (Right to Buy) · Derivative 15,048 $0.00 Strike: $1.70 $0.00
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · derivative · entry 5

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,952

Underlying: Ordinary Shares · 15,048 shares

Expires 2027-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F5 · derivative.exercise_date: The option is fully vested.

F4 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 4,952 $8.92 $44,175.80
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 4

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,440

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

F3 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 4,952 $0.50 $2,494.82
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 3

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 15,048 $8.92 $134,240.20
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,440

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

Read SEC document
April 29, 2025 Filed May 2, 2025 00:53 UTC Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 15,048 $1.70 $25,581.60
Disclosure

SEC source: 0001104659-25-043644 · tm2513834-1_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 Exercise / conversionShare Options (Right to Buy) · Derivative 39,616 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · derivative · entry 6

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,384

Underlying: Ordinary Shares · 39,616 shares

Expires 2032-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F6 · derivative.exercise_date: The option is fully vested.

F1 · derivative.underlying_shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 Exercise / conversionShare Options (Right to Buy) · Derivative 120,384 $0.00 Strike: $1.70 $0.00
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · derivative · entry 5

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 120,384 shares

Expires 2027-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F5 · security: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F6 · derivative.exercise_date: The option is fully vested.

F1 · derivative.underlying_shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 39,616 $8.92 $353,406.41
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 4

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,440

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F4 · balance_after: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 39,616 $0.50 $19,958.54
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 3

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 SaleOrdinary Shares 120,384 $8.92 $1,073,921.59
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,440

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

Read SEC document
April 29, 2025 Filed May 22, 2025 20:05 UTC Amendment Verona Pharma plc VRNA · Entity 74409 Exercise / conversionOrdinary Shares 120,384 $1.70 $204,652.80
Disclosure

SEC source: 0001104659-25-051979 · tm2515898-1_4aseq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2 · security: Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F1 · balance_after: This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

Read SEC document
April 27, 2025 Filed Apr 29, 2025 22:05 UTC Scholar Rock Holding Corp SRRK · Entity 3721 GrantCommon Stock 500,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-041454 · tm2513505-4_4seq1.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

F2 · shares: Represents performance based RSUs subject to performance- and time-based vesting conditions (the "PSUs"). The amount reported herein represents the maximum number of shares of the Issuer's common stock that may be issued under this award. The shares subject to this PSU vest in tranches of a combination of performance vesting tied to the Issuer's common stock achieving certain price targets and time-based vesting over four years, provided the reporting person continues to have a service relationship with the Issuer on each such vesting date. Any PSUs that have not vested on or prior to April 27, 2029 will be forfeited for no consideration.

Read SEC document
April 27, 2025 Filed Apr 29, 2025 22:05 UTC Scholar Rock Holding Corp SRRK · Entity 3721 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-041454 · tm2513505-4_4seq1.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: Represents restricted stock units ("RSUs") subject to time-based vesting conditions. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on April 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on each such vesting date.

Read SEC document
April 25, 2025 Filed Apr 29, 2025 21:17 UTC Verona Pharma plc VRNA · Entity 74409 GrantRestricted Share Units · Derivative 96,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-25-041402 · tm2513544-9_4seq1.xml · derivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,000

Underlying: Ordinary Shares · 96,000 shares

Expires not disclosed

F1 · security: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · derivative.exercise_price: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F1 · shares: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F2 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: Represents an award of Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"). Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

Read SEC document
February 21, 2025 Filed Feb 24, 2025 21:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 303 $10.08 $3,052.97
Disclosure

SEC source: 0000950170-25-025634 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,129

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:11 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 13 $9.94 $129.22
Disclosure

SEC source: 0000950170-25-009197 · ownership.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,432

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025.

Read SEC document
January 23, 2025 Filed Jan 27, 2025 21:11 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 116 $9.45 $1,096.64
Disclosure

SEC source: 0000950170-25-009197 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,445

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025.

Read SEC document
January 10, 2025 Filed Jan 13, 2025 21:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 979 $0.44 $430.86
Disclosure

SEC source: 0000950170-25-004832 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,139,915

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 19, 2024 Filed Nov 20, 2024 21:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,186 $0.55 $1,747.52
Disclosure

SEC source: 0000950170-24-129259 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,140,894

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 05, 2024 Filed Nov 6, 2024 21:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,136 $0.86 $4,442.13
Disclosure

SEC source: 0000950170-24-122333 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,144,080

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 22, 2024 Filed Oct 23, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,882 $0.77 $1,445.00
Disclosure

SEC source: 0000950170-24-116648 · ownership.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,149,216

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 21, 2024 Filed Oct 23, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,546 $0.78 $1,204.33
Disclosure

SEC source: 0000950170-24-116648 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,151,098

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 940 $0.81 $765.91
Disclosure

SEC source: 0000950170-24-112914 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,152,644

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
August 19, 2024 Filed Aug 20, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,159 $0.76 $2,399.26
Disclosure

SEC source: 0000950170-24-099103 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,153,584

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 05, 2024 Filed Aug 7, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,251 $0.73 $3,858.43
Disclosure

SEC source: 0000950170-24-092809 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,156,743

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 22, 2024 Filed Jul 23, 2024 20:27 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,858 $0.74 $1,373.43
Disclosure

SEC source: 0000950170-24-085663 · ownership.xml · nonDerivative · entry 2

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,161,994

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 19, 2024 Filed Jul 23, 2024 20:27 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,542 $0.75 $1,156.65
Disclosure

SEC source: 0000950170-24-085663 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,163,852

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 02, 2024 Filed Jul 3, 2024 20:14 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 939 $0.72 $676.08
Disclosure

SEC source: 0000950170-24-081518 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,165,394

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · balance_after: Includes 36,337 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 28, 2024.

Read SEC document
May 17, 2024 Filed May 21, 2024 20:33 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,143 $0.75 $2,355.05
Disclosure

SEC source: 0000950170-24-062978 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,129,996

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 03, 2024 Filed May 7, 2024 20:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,957 $0.80 $3,945.77
Disclosure

SEC source: 0000950170-24-054511 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,133,139

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 29, 2024 Filed Apr 30, 2024 20:18 UTC Verona Pharma plc VRNA · Entity 74409 GrantShare Options (Right to Buy) · Derivative 240,000 $0.00 Strike: $1.93 $0.00
Disclosure

SEC source: 0001104659-24-054958 · tm2412993-5_4seq1.xml · derivative · entry 1

Sinha Vikas · CIK 0001337845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Ordinary Shares · 240,000 shares

Expires 2034-04-28

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.